Image for representational purpose only. (Photo | AP) 
India

SII applies for full market authorisation of Covishield as supplies of vaccine exceeded 125 crore doses

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government

PTI

NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawala on Friday said it has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government, which had in January this year granted emergency use authorisation in the country.

"Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission," Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.

Cong demands PM Modi's resignation for 'match-fixing' polls through CEC; demands suspension of SIR

One Assam Rifles jawan killed, four injured in suspected militant attack in Arunachal's Changlang district

NCERT book says Indian subcontinent saw invasions since 7th century, driven by territorial, religious motives

Asian Games 2026: Shooter Neeru ends India's wait, bags historic gold in trap discipline

Jaishankar flags US lack of understanding on cross-border terror concerns, says it impacts bilateral ties